This IFN activity could reflect in part the mechanism by which type I IFN exerts an essential role in controlling tumor immune response and acts as an antitumor agent when therapeutically administered to patients [3], [4], [14], [18], [19]. This evidence concerns the gene IFNA1 and neoplasm.